British doctor who helped fight Ebola praises an experimental vaccine
Dr Catherine Houlihan, from Aberdeen, returned home to the UK from the African nation in June after spending a month at the heart of the epidemic in the North Kivu province.
Congolese authorities and health workers vaccinated more than 200,000 people against Ebola in August, the government said on Sunday, using a Merck vaccine they hope will help rein in the world's second worst epidemic.
We describe reference materials that have been or are being developed for haemorrhagic fever viruses and consider the issues surrounding their production, particularly that of biosafety where the viruses require specialised containment facilities. Finally, we advocate the use of reference materials at early stages, including research and development, as this helps produce reliable assays and can smooth the path to regulatory approval.
ConclusionsOur projections are concentrated in a range up to about 300 cases beyond those already reported. While a catastrophic outbreak is not projected, it is not ruled out, and prevention and vigilance are warranted. Prospective validation of our models in real time allowed us to generate more accurate short-term forecasts, and this process may prove useful for future real-time short-term forecasting. We estimate that transmission rates are higher than would be seen under target levels of 62% coverage due to contact tracing and vaccination, and this model estimate may offer a surrogate indicator for the outbreak response challenges.
(KAMPALA, Uganda) — Researchers in Uganda have launched the largest-ever trial of the experimental Ebola vaccine that is expected to be deployed in neighboring Congo, where a deadly outbreak has killed over 1,800 people. The trial of the Janssen Pharmaceuticals vaccine involves up to 800 people in the western district of Mbarara and is supported by Doctors without Borders and the London School of Hygiene and Tropical Medicine. Pontiano Kaleebu, a Ugandan researcher who leads the trial, said Friday that he regrets that the Janssen vaccine has not yet been deployed in Congo. The health minister there who stepped down l...
More than 1,500 deaths and 2,500 people sickened – that’s the recent account of the ebola outbreak in the Democratic Republic of Congo (DRC) raging in the country since last August, and recently declared a public health emergency of international concern. Experts say efforts to contain the virus are hindered by biological, public health, political, and cultural issues, but we looked around what digital health technologies could do to mitigate the spread and the devastation of the infectious disease. The Spaghetti-like virus… The lethal Ebola virus first appeared in 1976 around a river in Congo &nda...
Discussion Dengue is an important arboviral infection that affects about 40% of the world population. It is found mainly in topical and subtropical areas of the world mainly in developing countries but it range is spreading including the United States. A review of common arboviruses can be found here. It is a flaviavirus with 4 distinct serotypes named DENV-1 through DENV-4 and is spread by A. aegypti a day biting mosquito. Infection with one serotype confers immunity to that serotype but not the others. It does offer some protection for cross-infection but this only lasts a few months. Incubation period is 3-14 days with ...
After the resignation of the country ’s health minister, the president will take over the response to the epidemic and distribute a new vaccine.
Congo's health minister resigned on Monday after being stripped of responsibility for managing the country's Ebola outbreak, potentially paving the way for the introduction of a second vaccine to contain the spreading epidemic.Reuters Health Information
Congo's health minister resigned on Monday after being stripped of responsibility for managing the country's Ebola outbreak, potentially paving the way for the introduction of a second vaccine to contain the spreading epidemic.
Condition: Ebola Virus Disease Intervention: Drug: Ad26.ZEBOV/MVA-BN-Filo Sponsors: MRC/UVRI Uganda Research Unit on Aids; Epicentre, Paris, France and Mbarara, Uganda; Janssen Pharmaceutica N.V., Belgium; Coalition for Epidemic Preparedness Innovations Not yet recruiting